Table 4 Comparison of participants with and without preference for long-acting drugs administered every 8 weeks
With preference for long-acting drugs | Without preference for long-acting drugs | P value | |
|---|---|---|---|
Age, median (IQR)-yr | 45 (39–50) | 48 (40–57) | 0.007a) |
Age group, n (%) | 0.001b) | ||
< 50 years | 75 (4) | 319 (5) | |
≥ 50 years | 27 (96) | 246 (95) | |
Sex, n (%) | 0.805b) | ||
Male | 98 (96) | 537 (95) | |
Female | 4 (4) | 28 (5) | |
CD4 cell counts, median (IQR)-cells/µL | 615 (475–755) | 580 (438–757) | 0.315a) |
HIV-RNA, n (%) | 1.000b) | ||
≤ 20 copies/mL | 91 (89) | 504 (89) | |
20-49 copies/mL | 8 (8) | 44 (8) | |
≥ 50 copies/mL | 3 (3) | 17 (3) | |
ART regimen consisting of the following tablet sizes, n (%) | 1.000b) | ||
Tablets size less than 15 mm | 52 (51) | 291 (51) | |
Tablets size over 15 mm | 50 (49) | 274 (49) | |
Duration of receipt of overall ART (medication history), n (%) | 0.122b) | ||
< 3 years | 20 (20) | 75 (13) | |
≥ 3 years | 82 (80) | 490 (83) | |
Employment, n (%) | 0.469b) | ||
Employed | 86 (86) | 444 (79) | |
Unemployed | 14 (14) | 93 (16) | |
Unknown | 2 (2) | 28 (5) | |
Frequency of daily dosage, n (%) | 0.908b) | ||
Once a day | 58 (57) | 334 (59) | |
Twice a day | 19 (19) | 109 (19) | |
Three times a day | 14 (14) | 68 (12) | |
4 or more times a day | 11(10) | 54 (10) | |
Concomitant medications*, n (%) | 0.913b) | ||
With concomitant medications | 57 (56) | 322 (57) | |
Without concomitant medications | 44 (43) | 241 (43) | |
Unknown | 1 | 2 | |
Daily tablet dosage†, n (%) | 0.851b) | ||
1 tablet/day | 26 (25) | 167 (30) | |
2 tablets/day | 22 (22) | 117 (21) | |
3 tablets/day | 15 (15) | 84 (15) | |
4 or more tablets/day | 39 (38) | 197 (35) | |